Učitavanje...
Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase
Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton’s tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In preclinical studies, ibrutinib bound to Bruton’s tyrosine kinase with high affinity, leading to inhibition...
Spremljeno u:
| Izdano u: | Future Oncol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2014
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4632638/ https://ncbi.nlm.nih.gov/pubmed/24941982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.51 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|